A new wave of scientific interest is spotlighting GOT2—glutamic-oxaloacetic transaminase 2—as a compelling therapeutic target ...

Unlike liver disease linked to alcohol abuse, MASLD is driven largely by metabolic imbalances, poor diet and sedentary ...

MASLD, previously called ‘fatty liver disease’, is a ticking timebomb, affecting 30 to 40 per cent of adults – most of whom ...

The researchers analyzed gene and protein expression, along with lipid profiles, in the bone marrow of mice whose Elovl2 gene ...

An international team of microbiologists from the Medical University of Graz, the DSMZ—German Collection of Microorganisms ...

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

New research presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) and published in The Journal ...

April 15, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated ...